Improving T‑cell immunotherapy by targeting tumor metabolism
Exploiting tumor metabolism to optimize T cell therapy
This work sees if changing how lymphoma tumors use energy can help T‑cell immunotherapy work better for adults with diffuse large B‑cell lymphoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11178624 on NIH RePORTER |
What this research studies
Researchers at Weill Cornell will study how tumor metabolism affects T‑cell responses in diffuse large B‑cell lymphoma, focusing on the aggressive MCD subtype. They will use laboratory models, imaging tools, and experiments that change tumor glycolysis to observe effects on the tumor microenvironment and immune cells. Much of the work uses animal tumor models and advanced imaging to track tumor growth, metastasis, and anti‑tumor immune activity during immunotherapy. The team aims to identify molecular mechanisms of immune evasion and find approaches that could make T‑cell therapies more effective.
Who could benefit from this research
Good fit: Adults (21+) with diffuse large B‑cell lymphoma, especially those with relapsed, refractory, or the aggressive MCD subtype, would be most relevant to this research.
Not a fit: People without DLBCL, those whose lymphoma responds well to standard treatments, or patients with unrelated cancers are unlikely to directly benefit from this specific work.
Why it matters
Potential benefit: If successful, this work could lead to strategies that make T‑cell immunotherapies more effective for people with therapy‑resistant DLBCL.
How similar studies have performed: CAR T‑cell therapies have helped some patients with B‑cell lymphomas, but combining immunotherapy with tumor metabolic targeting is largely experimental with promising preclinical results.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Serganova, Inna — Weill Medical Coll of Cornell Univ
- Study coordinator: Serganova, Inna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.